Artimplant AB
Hulda Mellgrens gata 5
SE-421 32 Västra Frölunda
SWEDEN

Phone +46 (0)31 746 56 00
Fax +46 (0)31 746 56 60
Web www.artimplant.com
Org. No 556404-8394

Press Release
Västra Frölunda, Sweden, November 21, 2006

Artimplant recalls its odontology product Bone Scaffold from the market

Artimplant recalls its odontology product Bone Scaffold intended to increase bone volume of bone defects in the mouth. The Company has acquired data showing that necessary bone formation is not achieved.

The product has been implanted in less than 20 patients.

As communicated in the third quarter interim report 2006, Artimplant develops a new design that is expected to better meet the functional demands. Clinical evaluation is planned to be performed during 2007.

Artimplant CEO, Hans Rosén says;

"Bone Scaffold has been used by a selected number of clinics with the purpose of increasing bone volume, mainly in the upper jaw at so called sinus lift. Data from six months follow up show that so called osteoid tissue, the initial phase of bone formation is integrated into Artelon®, but mineralized bone is not formed. Because of this, Artimplant has decided to recall the product from the market. In consultation with clinicians we believe we may have identified the problem as too small pores in the product. Our plan is to further develop Bone Scaffold by changing the structure of the material.

For additional information, please contact:

Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70, hans.rosen@artimplant.com

Web site: **www.artimplant.com**

About Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic, odontological and reconstructive surgery. The Company is engaged in the development, production and marketing of degradable implants designed to restore active lifestyles and improve quality of life. The proprietary technology Artelon®, a long-term degradable biomaterial, offers new solutions to unmet clinical needs and opens new markets. Artimplant's business model is that of licensing its products and technology to global partners. The Company currently has six licensing agreements and one distribution agreement with three global partners. Artimplant is a public company, listed on the Nordic Exchange in the Small Cap segment and in the healthcare sector.

Forward-looking statements

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.